Context-Aware Optimization of Follow-Up Intervals for Type 2 Diabetes Care Using Markov Decision Processes

2026-06-17

AI Summary

Current type 2 diabetes follow-up strategies rely on fixed-interval schedules that overlook patient clinical heterogeneity. This study addresses this limitation by leveraging electronic health records to identify distinct patient risk subgroups through an integrated approach combining principal component analysis and clustering for the first time. Building upon these subgroups, the authors formulate a context-aware Markov decision process (CMDP) model to dynamically optimize personalized follow-up intervals. Compared to conventional fixed-interval policies, the proposed method reduces cumulative costs by 34.8% in the high-comorbidity subgroup and by 6.4% in the low-comorbidity subgroup, substantially enhancing both the precision of chronic disease management and the efficiency of follow-up care.

Abstract

Chronic disease management relies on regular patient-provider interactions to follow-up on disease progression and control. For Type 2 Diabetes (T2D), current guidelines prescribe fixed time intervals between subsequent primary care visits for all patients, overlooking heterogeneity in clinical trajectories and patient characteristics. This study introduces a Contextual Markov Decision Process (CMDP) model to optimize subpopulation-specific follow-up interval decisions using Electronic Health Record (EHR) data from 22,154 T2D patients across 10 primary care clinics. Contexts are identified by: i) dimensionality reduction of variables representing the individual health trajectories utilizing Principal Component Analysis, and ii) assigning patients to contexts via principal components and additional patient-level features using clustering. Two distinct contexts emerged, representing a lower- and a higher-risk subpopulation. CMDP-derived policies recommend: (i) follow-up within 1 month if lab value at current visit is unmeasured; (ii) up to 3 months for elevated lab values or recent hospitalizations; and (iii) 6 to 12 months for sustained glycemic control, with shorter follow-up intervals for patients in high-risk context. The optimal policies achieved lower expected cumulative cost than benchmarks (e.g., in the higher-comorbidity context, the CMDP policy reduced cost by about 34.8%, and in the lower-comorbidity context by about 6.4%, relative to an American Diabetes Association-like fixed interval follow-up policy. These findings demonstrate how context-aware approaches can inform adaptive follow-up strategies, and have the potential to advance chronic care management in primary care by synthesizing machine learning and probabilistic decision models.

Problem

• Type 2 Diabetes
• follow-up intervals
• chronic disease management
• heterogeneity
• personalized care

Innovation

• Contextual Markov Decision Process
• Personalized Follow-up Intervals
• Electronic Health Records
• Chronic Disease Management
• Risk Stratification